These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2182899)

  • 1. The microbiology, chemotherapy, and surgical treatment of tuberculosis.
    Boyars MC
    J Thorac Imaging; 1990 Apr; 5(2):1-7. PubMed ID: 2182899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis due to Mycobacterium kansasii.
    Elder JL; Edwards FG; Abrahams EW
    Aust N Z J Med; 1977 Feb; 7(1):8-13. PubMed ID: 266899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections].
    Rowińska-Zakrzewska E; Słupek A; Graczyk J; Zwolska-Kwiek Z; Augustynowicz-Kopeć E; Stambrowska A; Byszewska D; Latoś E; Pilarska A; Andrzejczyk Z
    Pneumonol Alergol Pol; 1992; 60(9-10):81-8. PubMed ID: 1338003
    [No Abstract]   [Full Text] [Related]  

  • 4. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
    Ahn CH; Lowell JR; Ahn SS; Ahn SI; Hurst GA
    Am Rev Respir Dis; 1983 Dec; 128(6):1048-50. PubMed ID: 6650978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of tuberculosis.
    Armstrong EM
    J Natl Med Assoc; 1983 Jul; 75(7):714-8. PubMed ID: 6887276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifabutin in the treatment of cavitary lung disease due to Mycobacterium gordonae.
    Nathan V; Mehta JB; Dralle W
    South Med J; 1993 Jul; 86(7):839-41. PubMed ID: 8391724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis.
    Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW
    Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Campbell IA
    Tuber Lung Dis; 1995 Dec; 76(6):583. PubMed ID: 8593385
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary disease due to Mycobacterium terrae.
    Palmero DJ; Teres RI; Eiguchi K
    Tubercle; 1989 Dec; 70(4):301-3. PubMed ID: 2626806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary infection with mycobacterium xenopi: review of treatment and response.
    Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
    Thorax; 1984 May; 39(5):376-82. PubMed ID: 6740540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction aspects of antimycobacterial drugs in the chemotherapy of tuberculosis. I. Role of individual antituberculous drugs in drug regimens used in the chemotherapy of human tuberculosis.
    Trnka L; Tousek J
    Chemotherapy; 1974; 20(3):165-76. PubMed ID: 4136827
    [No Abstract]   [Full Text] [Related]  

  • 12. Pulmonary disease due to Mycobacterium massiliense.
    Mitra S; Tapadar SR; Banerjee D; Bhattacharjee S; Dey S; Kundu S
    Indian J Chest Dis Allied Sci; 2012; 54(1):53-7. PubMed ID: 22779125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fever and thin-walled cavitary lung lesions].
    Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary drug-resistant tuberculosis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis.
    Steiner P; Rao M; Mitchell M; Steiner M
    Am J Dis Child; 1985 Aug; 139(8):780-2. PubMed ID: 3927707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary disease caused by nontuberculosis mycobacteria.
    Tellis CJ; Putnam JS
    Med Clin North Am; 1980 May; 64(3):433-46. PubMed ID: 6993809
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical features of pulmonary disease caused by Mycobacterium fortuitum].
    Hagiwara E; Sekine A; Sato T; Baba T; Shinohara T; Endo T; Sogo Y; Nishihira R; Komatsu S; Matsumoto Y; Ogura T; Takahashi H
    Nihon Kokyuki Gakkai Zasshi; 2008 Oct; 46(10):788-92. PubMed ID: 19044027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis.
    Salzer HJ; Wassilew N; Köhler N; Olaru ID; Günther G; Herzmann C; Kalsdorf B; Sanchez-Carballo P; Terhalle E; Rolling T; Lange C; Heyckendorf J
    Respiration; 2016; 92(4):199-214. PubMed ID: 27595540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis and nontuberculous mycobacterial isolates among patients with recent HIV infection in Mozambique.
    Nunes EA; De Capitani EM; Coelho E; Panunto AC; Joaquim OA; Ramos Mde C
    J Bras Pneumol; 2008 Oct; 34(10):822-8. PubMed ID: 19009216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Mycobacterium xenopi in human disease.
    Simor AE; Salit IE; Vellend H
    Am Rev Respir Dis; 1984 Mar; 129(3):435-8. PubMed ID: 6703502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.